Suppr超能文献

携带 、 和 同时突变的费城阴性骨髓增殖性肿瘤患者的遗传和临床特征。

Genetic and Clinical Characteristics of Patients with Philadelphia-Negative Myeloproliferative Neoplasm Carrying Concurrent Mutations in , and .

机构信息

Department of Hematology, Affiliated Hospital of Guizhou Medical University, Guizhou Provincial Institute of Hematological Malignancies, Guiyang, China.

Department of Clinical Laboratory Medicine, 56663Guizhou Provincial People's Hospital, Guiyang, China.

出版信息

Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231154092. doi: 10.1177/15330338231154092.

Abstract

Simultaneous mutations in Janus kinase 2 (, calreticulin and myeloproliferative leukemia genes are generally not considered for characterizing Philadelphia-negative myeloproliferative neoplasms (MPNs), leading to misdiagnosis. Sanger sequencing and quantitative polymerase chain reaction were used to detect gene mutations in patients with MPN. We retrospectively screened the data of patients with double mutations in our center and from the PubMed database. Two patients tested positive for both and mutations (2/352 0.57%) in our center, while data of 35 patients from the PubMed database, including 26 patients with essential thrombocythemia (ET), 6 with primary myelofibrosis (PMF), 2 with unexplained thrombosis, and 1 with polycythemia vera were screened for double mutations. Among these mutations, co-mutation of constituted the majority (80.0%), when compared with (17.1%) and (2.9%) mutations. Moreover, patients with concurrent mutational myeloproliferative neoplasm (MPN) were relatively older (  =  .010) with significantly higher platelet counts than their counterparts with single gene mutations ( < .001). The occurrence of palpable splenomegaly ( < .001) and leukocyte count (  =  .041) were also significantly different between patients with single and simultaneous gene mutations. These 4 risk factors also showed significant test effectiveness in the ET and PMF cohorts ( < .05). In terms of clinical characteristics of patients with ET, those with - mutation had higher but normal hemoglobin levels (  =  .0151) than those carrying - mutation. From a clinical perspective, patients with multiple mutational MPN are different from those with single gene mutations. The poor treatment response by patients in our center and unfavorable indicators for patients with co-mutations in published literature indicate that customized treatment may be the best choice for patients with MPN carrying co-mutations.

摘要

同时存在 JAK2()、钙网蛋白和骨髓增生性白血病基因的突变通常不被认为是费城阴性骨髓增生性肿瘤(MPN)的特征,这导致了误诊。我们使用 Sanger 测序和实时定量聚合酶链反应来检测 MPN 患者的基因突变。我们回顾性地筛选了我们中心和 PubMed 数据库中双突变患者的数据。我们中心有 2 例患者(2/352,0.57%)同时存在和突变阳性,而从 PubMed 数据库中筛选了 35 例患者的数据,其中包括 26 例特发性血小板增多症(ET)、6 例原发性骨髓纤维化(PMF)、2 例不明原因血栓形成和 1 例真性红细胞增多症。在这些突变中,与和突变(分别为 17.1%和 2.9%)相比, 共突变构成了大多数(80.0%)。此外,同时存在突变性骨髓增生性肿瘤(MPN)的患者年龄较大(=0.010),血小板计数明显高于单基因突变患者(<0.001)。可触及脾肿大(<0.001)和白细胞计数(=0.041)的发生在单基因突变和同时基因突变患者之间也有显著差异。这 4 个危险因素在 ET 和 PMF 队列中也表现出显著的检验效果(<0.05)。就 ET 患者的临床特征而言,携带 - 突变的患者血红蛋白水平较高但正常(=0.0151),而携带 - 突变的患者则较低。从临床角度来看,多发性突变性 MPN 患者与单基因突变患者不同。我们中心患者的治疗反应不佳以及文献中报道的合并突变患者的不利指标表明,针对携带合并突变的 MPN 患者,定制治疗可能是最佳选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ac0/9905029/5ebe7c81a32b/10.1177_15330338231154092-fig1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验